Christopher Lee Colglazier, M.D.

2616 Legends Way Crestview Hills, KY 41017 Cell: 859-663-7555 Email: leecolglazier@gmail.com

Current Position		
Rheumatology Physician Tristate Arthritis and Rheumatology Crestview Hills, KY	7/2005 - Current	
Training		
Rheumatology Fellowship Program Wake Forest University Winston-Salem, NC	7/2003 – 6/2005	
Internal Medicine Residency Program Wake Forest University Winston-Salem, NC	7/2000 – 6/2003	
Education		
M.D. University of Cincinnati College of Medicine Cincinnati, OH	8/1996 – 6/2000	
Bachelor of Arts in Chemistry / Honors Division Certificate in Business Management Indiana University Bloomington, IN	8/1992 – 5/1996	
Licensure and Certification		
Ohio Medical Board Licensure (09834) Kentucky Medical Board Licensure (39193) DEA (BC7760944) National Provider Number (1679555486)	September 21, 2011 March 17, 2005 May13, 2002	
UPIN (H25240) North Carolina Medical Board Licensure (2001-01436)	Nov 16, 2001	
ABIM Rheumatology Certification (number 221871) American Board of Internal Medicine Certification (number 221871) United States Medical Licensing Exam Step 3 (5-039-295-0) United States Medical Licensing Exam Step 2 (5-039-295-0) United Stated Medical Licensing Exam Step 1 (5-039-295-0)	Oct, 2005 Aug, 2003; Oct 2012 Sept 6, 2001 Aug 23, 1999 June, 1998	
Certification in Clinical Densitometry, ISCD Certification of Human Research Protection Education Advanced Cardiac Life Support Basic Cardiac Life Support Emergency Medical Technician	July 18, 2004 Nov 13, 2003 Jan, 2005 Dec, 2004 May, 1995	
Awards		

Awards

Top Doctor, Cincinnati Magazine. 2010, 2011, 2012, 2013, 2014, 2015, 2016 Patient's Choice Award 2010, 2011. 2012, 2013, 2014 America's Most Compassionate Doctor 2008, 2009, 2010, 2011, 2012, 2013, 2014 American Registry Arthritis Foundation "My Doc Rocks" Award. 2011, 2012, 2013 American College of Rheumatology Distinguished Fellow Award, 2005 Outstanding Internal Medicine Resident of the Year Award, Wake Forest 2002 Honorable Mention, University of Cincinnati College of Medicine, 2000 Graduation with Distinction, Indiana University, 1996 General Honor's program, Indiana University, 1996 Highest Scholastic Achievement Award, Indiana University, 1993 Alpha Lambda Delta and Phi Eta Sigma Honor Fraternities, Indiana University, 1993

Practice Positions

Implementation of Electronic Health Records 2008 – Current Compliance officer Meaningful Use 2012 – Current Implementation and maintenance of website, including patient education and social media. 2006 – current. Quality Measures Compliance officer PQRS (2007?), Electronic Prescribing

Publications

Christopher Lee Colglazier; Paul G. Sutej; Kenneth S. O'Rourke. Severe Refractory Fingertip Ulcerations in a Patient With Scleroderma: Successful Treatment with Sildenafil. *Journal of Rheumatology*, Nov 2005; 32:12.

Colglazier, C; Sutej, P. Laboratory Testing in the Rheumatic Diseases: A Practical Review. *Southern Medical Journal*. Feb2005; 98:185-191.

Pincus, Swearingen, Bergman, Colglazier. RAPID3 (Routine Assessment of Patient Index Data) on a MDHAQ (Multidimentional Health Assessment Questionaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories. *Arthritis Care and Research* February 2010 vol 62 no 2

C. L. Colglazier, C. Swearingen, A. Kaell, A. Kunath, E. Siegel, M. Bergman, Y. Yazici, T. Pincus. Time to Score Indices to Assess Clinical Status in RA: Disease Activity Score (DAS28), Clinical Disease Activity Index (CDAI), Easy Rheumatoid Arthritis Measure (ERAM) and Routine Assessment of Patient Index Data (RAPID3) in Usual Clinical Care. *Arthritis & Rheumatism* Sept 2008; vol 58 no 9 (abstract supplement) abstract # 1582.

T. Pincus, C. Swearingen, M. Bergman, C. L. Colglazier et al. Further Evidence of Significant Associations of Routine Assessment of Patient Index Data 3 (RAPID3) with Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI) in Patients with Rheumatoid Arthritis (RA)*Arthritis & Rheumatism* Sept 2008; vol 58 no 9 (abstract supplement) abstract # 1384.

Lee Colglazier, Frederick Wolfe, Kaleb Michaud. Rheumatoid arthritis (ra) patients are less likely to be treated with prophylactic aspirin despite an increased risk of myocardial infarction [abstract].*Arthritis & Rheumatism* Sept 2005; vol 52 no 9 (abstract supplement) abstract #1904.

Podium Presentation: 2005 Annual Scientific Meeting, San Diego Nov 12-17.

Kelly A Rouster-Stevens; Elisa Y Rhew; Christian T Sinclair; Christopher Lee Colglazier Rheumatology Fellow Interaction with Pharmaceutical Industry: Survey Results [abstract]. *Arthritis & Rheumatism* Sept 2005; vol 52 no 9 (abstract supplement) abstract #1855.

Professional Organization Positions

012
010
011
012
012
- 11/2005
- 11/2005
10/2004
6/2002

Lectures / Public Relations

Attending for Medical training University of Cincinnati Medical School

Jewish Hospital Internal Medicine	2008 - Current	
St. Elizabeth Family Medicine	2005 - Current	
Lecturer: Resident Core Conference Series, St. Elizabeth Hospital	2005 – Current	
Lecturer: Pfizer Lyrica and Fibromyalgia	2008 – Current	
Media Release: 2005 ACR Annual Scientific Meeting	Nov 12-17, 2005	
Rheumatoid arthritis patients are less likely to be treated with prophylactic aspirin despite an increased risk of		
myocardial infarction		
Lecturer: Medical Student Core Curriculum Conferences: "Rheumatology"; Wake Forest July 2003 - June 2005		
Lecturer: Internal Medicine Board Review Series: "Rheumatology"; Wake Forest	July 2003 - June 2005	
Speaker: WFMY News "2 Your Health" Public Education Series: "Arthritis"	April 11, 2005	
Speaker: WFMY News "2 Your Health" Public Education Series: "Fibromyalgia"	May 2, 2005	
Speaker: WFMY News "2 Your Health" Public Education Series: "Lupus"	May 19, 2005	
Lecturer: NC Northwest AHEC (Area Health Education Center) CME Program	March 2005	
"Updates in Rheumatology"		

Professional Memberships

American College of Rheumatology	2003 - Current
American College of Physicians / American Society of Internal Medicine	2000 - Current
American Medical Association	1996 – Current
Kentucky Rheumatology Association	2005 - Current
American Society of Clinical Rheumatologists	2005 - Current
Kentucky Pain Society	2008 - Current

Research

Selected for the Health Outcomes Research Epidemiology Fellowship Program through the Arthritis Research Center Foundation / National Databank of Rheumatic Diseases (NDB). Program Directors: Frederick Wolfe, NDB; Theodore Pincus, Vanderbilt University; Hyon Choi, Harvard. July 2004 – June 2005.

Principal-Investigator May 2004 - May 2005 The National Data Bank for Rheumatic Diseases Data Collection Project IRB BG04-272

Clinical Research Trial Participation

Principal Investigator 2012 - 2014 "Treating to Target (T2T) for patients with Rheumatoid Arthritis in a US population: Outcomes and feasibility" CORRONA

Co-Investigator, 1/2005 - 6/2005.

La Jolla Parmaceuticals: A Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 100 mg and 300 mg of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease. Wake Forest University

Sub-Investigator, April 2004 - June 2005.

Human Genome Science, Inc: A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-BTM Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Systemic Lupus Erythematosus (SLE) Wake Forest University

Sub-Investigator, April 2004 - June 2005.

Roche/Genentech/IDEC: A Randomised, Multifactorial, Double-Blind, Parallel-Group, Dose-Ranging Study of the Efficacy and Safety of Rituximab (MabThera/Rituxan®) in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis.Protocol WA17043/U2644g Wake Forest University

Sub-Investigator, April 2004 - June 2005.

Roche/Genentech/IDEC: An open label study of the efficacy and safelty of re-treatments with Rituximab(MabThera/Rituxan®) in patients with active rheumatoid arthritis. Protocol WA16855/U2653g

Wake Forest University

Sub-Investigator, April 2004 - June 2005. Human Genome Science, Inc: A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-BTM Antibody (Monoclonal Anti-BLyS Antibody) in subjects with Rheumatoid Arthritis (RA). LBRA01 Wake Forest University

Sub-Investigator, April 2004 - June 2005 LBRA99: A Multi—Center, Open-Label, Continuation Trial of LymphoStatBTM Antibody (Monoclonal Anti-BlyS Antibody) in Subjects with Rheumatoid Arthritis (RA) who Completed the Phase 2 Protocol LBRA01 Wake Forest University Sub-Investogator, April 2004 - June 2005 Immunex 16.0023: Open-Label Extension Treatment with TNFR:Fc for Participating Patients in TNFR:Fc Clinical Trial 16.0023

Sub Investigator, April 2004 - June 2005

Protocol # WA18063, A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.

Other Publications

Poster Presentation: Noureddine N, Colglazier, C, Brownlee, N, Daniel, K. Hemophagocytic Syndrome; a Rare Complication of Systemic Lupus Erythematosus.2005 North Carolina American College of Physicians, American Society of Internal Medicine Conference.

Poster Presentation: 2003: Colglazier, C, Kimberly, J "An Evidence-Based Review of Tube Feeding Practices." American College of Physicians, American Society of Internal Medicine conference

Other Activities

Good Samaritan Free Health Center Volunteer, 2012 - 2015 Hospice of Cincinnati Volunteer. 2007 – 2012 Speaker Consultant UCB 2012 – Current Abbott 2011 - 2015 Forest 2010-2011 Pfizer 2007-2010